Russia’s Sputnik V vaccine 1st batch will arrive in India by May 1
By Sanjay Maurya
- RDIF announced on 27th April that it will export the 1st batch of the Sputnik V vaccine to India starting 1st May 2021.
- On 1st May India expands its Covid-19 vaccination campaign to all adults.
- RDIF is working with 6 firms in India namely Hetero Biopharma, Gland Pharma, Stelis Biopharma, Panacea Biotech, Virchow Biotech, and Shilpa Medicare jointly with Sputnik V.
Russia’s Sputnik V vaccine 1st batch will arrive in India by 1st May
The Russian Direct Investment Fund (RDIF) announced on 27th April that it will export the 1st batch of the Sputnik V vaccine to India starting May, the day India expands its Covid-19 vaccination campaign to all adults.
Reddy’s laboratories announced that there was no specific date of launch, stating that the company had previously stated that deliveries would begin in late May, but that schedule has now been changed to sometime in May. The company said, “conversation is going on regarding the prices and the number of Sputnik V vaccine doses between RDIF and the government.”
The Russian Direct Investment Fund (RDIF) announced last year that it would be priced below $ 10 (INR 750) per dose in international markets. Vaccine prices vary from country to country.
Dr. Reddy’s management had previously stated that the initial quantity of vaccine supplied in India would be limited as it would be mainly imported from Russia. However, RDIF’s manufacturing partners in India will begin production of the injection locally in July. After that, the supply will increase.
RDIF is working with six companies in India: Hetero Biopharma, Gland Pharma, Stelis Biopharma, Panacea Biotech, Virchow Biotech and Shilpa Medicare jointly with Sputnik V. Commissioned the construction of more than 850 million. Dr. Reddy’s Pact with RDIF 250 to distribute. The supply of the million-dose vaccine is critical to meet the growing demand when adult vaccination begins on 1st May.
The reason for Sputnik V is significant due to the Russian Direct Investment Fund (RDIF) model, which aims to establish business relationships with other pharmaceutical companies and vaccine manufacturers to producing and supply Sputnik V to expand its production. Partnership transfer with the 7 pharmaceutical Indian companies for producing and sell Sputnik V in the country.
Dr. Reddy said, Approving the vaccine would mean not only makes the vaccine but also the half-dozen other facilities that make it together, adding millions of doses of COVID-19 vaccines to the delivery system on time. To rapidly increase production capacity, the government may see Sputnik V as a more convenient way to increase vaccine availability without making financial commitments.